Methods and compositions for the treatment of body composition disorders

1 - 119 . (canceled)

120 . A method of inhibiting Δ5-desaturase, which comprises contacting Δ5-desaturase with a compound of formula I:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

Q 1 is C or N;

Q 2 is C or N;

X is C(R 4 R 5 ) or N(R 4 );

Y is C(R 4 ), C(R 4 R 5 ), N, or N(R 4 );

A is nothing (i.e., NR 2 is directly attached to the optionally substituted phenyl moiety), CH 2 , C(O), or SO 2 ;

each R 1 is independently OR 1A , N(R 1A ) 2 , NC(O)R 1A , hydrogen, cyano, nitro, halo, or optionally substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl;

each R 1A is independently hydrogen or optionally substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl;

R 2 is hydrogen or optionally substituted alkyl;

each R 3 is independently OR 3A , N(R 3A ) 2 , NC(O)R 3A , hydrogen, cyano, nitro, halo, or optionally substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl;

each R 3A is independently hydrogen or optionally substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl;

each R 4 is independently hydrogen or optionally substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl;

each R 5 is independently hydrogen or optionally substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl;

n is 1-4 if Q 1 and Q 2 are both C, 1-3 if one of Q 1 and Q 2 are N, or 1-2 if both Q 1 and Q 2 are N; and

m is 1-4.

121 . (canceled)

122 . (canceled)

123 . A method of treating, preventing or managing a body composition disorder, which comprises administering to a patient in need thereof a therapeutically or prophylactically effective amount of a potent Δ5-desaturase inhibitor of formula I:

or a pharmaceutically acceptable salt or solvate thereof, wherein:

Q 1 is C or N;

Q 2 is C or N;

X is C(R 4 R 5 ) or N(R 4 );

Y is C(R 4 ), C(R 4 R 5 ), N, or N(R 4 );

A is nothing (i.e., NR 2 is directly attached to the optionally substituted phenyl moiety), CH 2 , C(O), or SO 2 ;

each R 1 is independently OR 1A , N(R 1A ) 2 , NC(O)R 1A , hydrogen, cyano, nitro, halo, or optionally substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl;

each R 1A is independently hydrogen or optionally substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl;

R 2 is hydrogen or optionally substituted alkyl;

each R 3 is independently OR 3A , N(R 3A ) 2 , NC(O)R 3A , hydrogen, cyano, nitro, halo, or optionally substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl;

each R 3A is independently hydrogen or optionally substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl;

each R 4 is independently hydrogen or optionally substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl;

each R 5 is independently hydrogen or optionally substituted alkyl, aryl, alkylaryl, arylalkyl, heterocycle, alkylheterocycle or heterocyclealkyl;

n is 1-4 if Q 1 and Q 2 are both C, 1-3 if one of Q 1 and Q 2 are N, or 1-2 if both Q 1 and Q 2 are N; and

m is 1-4.

124 . (canceled)

125 . (canceled)

126 . The method of claim 123 , wherein the metabolic or body composition disorder decreased glucose tolerance, diabetes (Type I or II), insulin resistance, non-insulin-dependent diabetes mellitus, obesity, or Syndrome X.

127 . The method of claim 123 , which does not substantially affect the appetite of the patient.

128 . The method of claim 123 , wherein the potent Δ5-desaturase inhibitor is of formula I(a):

129 . The method of claim 123 , wherein the potent Δ5-desaturase inhibitor is of formula I(b):

130 . The method of claim 123 , wherein the potent Δ5-desaturase inhibitor is of formula I(c):

131 . The method of claim 123 , wherein the potent Δ5-desaturase inhibitor is of formula I(d):

132 . The method of claim 123 , wherein the potent Δ5-desaturase inhibitor is of formula I(e):

133 . The method of claim 123 , wherein both Q 1 and Q 2 are CR 1 .

134 . The method of claim 123 , wherein X is N(R 4 ).

134 . The method of claim 123 , wherein Y is N or N(R 4 ).

135 . The method of claim 123 , wherein A is a bond.

136 . The method of claim 123 , wherein R 1 is not hydrogen.

137 . The method of claim 123 , wherein R 1 is halo or optionally substituted lower alkyl, aryl, or heteroaryl.

138 . The method of claim 123 , wherein R 1 is OR 1A .

139 . The method of claim 138 , wherein R 1A is lower alkyl.

140 . The method of claim 123 , wherein n is 1 or 2.

141 . The method of claim 140 , wherein n is 1.

142 . The method of claim 123 , wherein R 2 is hydrogen.

143 . The method of claim 123 , wherein R 2 is lower alkyl.

144 . The method of claim 123 , wherein R 3 is halo or optionally substituted lower alkyl, aryl, or heteroaryl.

145 . The method of claim 144 , wherein R 3 is optionally substituted lower alkyl.

146 . The method of claim 144 , wherein R 3 is halo.

147 . The method of claim 123 , wherein R 3 is OR 3A .

148 . The method of claim 147 , wherein R 3A is lower alkyl.